The Society for Vascular Surgery (SVS) announced the release of updated clinical guidelines for the management of intermitten ...
Although pentoxifylline and cilostazol may provide symptomatic relief, the management of IC must address the underlying problem of PVD. Resolution of risk factors, such as smoking, diabetes, ...
The mainstays of therapy for IC are risk-factor modification, exercise, and antiplatelet therapy. If these prove inadequate, treatment with pentoxifylline or cilostazol is reasonable. a Trials ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback